Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VNRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVolitionRx director Mickie Henshall to depart board; no disagreement cited
Filed May 15, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
low
Director Mickie Henshall, who joined the board in August 2022, will not stand for re-election at the 2026 Annual Meeting. The filing explicitly states her departure involves no disagreement with company operations, policies, or practices.
Item 5.02 verify on EDGAR → -
low
Board size will shrink from eight to seven directors effective immediately before the 2026 Annual Meeting, a planned reduction tied to Henshall's departure rather than any governance restructuring.
Item 5.02 verify on EDGAR →
Summary
VolitionRx filed a routine director departure notice on May 15, 2026, disclosing that Mickie Henshall will not seek re-election at the upcoming annual meeting. Henshall has served on the board since August 2022. The company explicitly stated her decision did not involve any disagreement on operations, policies, or practices—standard language that helps distinguish voluntary departures from contentious exits.
For retail investors, this is a low-impact administrative event. Director turnover is normal corporate housekeeping, especially when timed to annual meetings and accompanied by explicit no-disagreement language. The board will simply operate with seven members instead of eight going forward. Watch the proxy statement for the annual meeting to see who the remaining director nominees are and whether the company adds any new independent directors to fill skill gaps.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify